138avap presentation ramayya

Post on 10-Apr-2018

219 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 1/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 2/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 3/94

Pneumonia can be a life threatening

condition

Is Something Serious ? Hospital-acquired

pneumonia (HAP)

and ventilator-

associated

pneumonia (VAP), is

an important cause

of morbidity andmortality in

hospitalized patients.

3doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 4/94

Ventilator associated pneumonia

Ventilator associated pneumonia (VAP) is

defined as nosocomial pneumonia occurring

in a patient after 48 hours of mechanical

ventilation via a tracheal or tracheostomy

tube. It is commonly classified as either early

onset (occurring within 96 hours of start of 

mechanical ventilation) or late onset (>96hours after start of mechanical ventilation)

doctortvrao@gmail.com 4

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 5/94

Early concepts

As early as 1972, studies have shown that theairway of mechanically ventilated patientsquickly becomes colonized with gram-negative

organisms. In the past, it was thought thatpathogens came from the ventilatorequipment in use. However, as the problemwas studied and evidence accumulated, it

became evident that the origin of the VAP wasfrom a source other than the ventilatorequipment.

5doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 6/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 7/94

Centres for Disease and Control

The diagnosis of pneumonia inmechanically ventilatedpatients is difficult, and

still there is no "gold-standard" diagnosticmethod. It is usually basedon the combination of clinical,radiological, and

microbiological criteriadefined by Centres forDisease and Control(CDC)

7doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 8/94

Challenge and Controversy

The diagnosis andmanagement of VAPremains one of the

mostcontroversial and challenging

topics inmanagement of critically ill patients.

8doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 9/94

Who are prone -High Risk Patients

For Sepsis ± Post op / post procedure / post trauma

 ± Post splenectomy (encapsulated organisms)

 ± Cancer

 ± Transplant / immune supressed

 ± Alcoholic / Malnourished

For Dying ± Genetic predisposition (e.g. meningococcus)

 ± Delayed appropriate antibiotics

 ± Yeasts and Enterococcus

 ± Site

For Both ± Cultural or religious impediment to treatment

9doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 10/94

Nosocomial infection are

Multidrug Resistant Many patients with HAP,

VAP, and HCAP are atincreased risk for colonization and

infection with MDR  pathogens

HAP and VAP are afrequent cause of nosocomial infection thatis associated with a higher crude mortality than other hospital-acquiredinfections

10doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 11/94

Aspiration Aspiration of colonized

pathogenicmicroorganisms on theoropharynx andgastrointestinal tract isthe main route for thedevelopment of VAP. Onthe other hand, the major

risk factor for VAP isintubation and theduration of mechanicalventilation

11doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 12/94

V ariation of Incidence Rate

In different studies, the incidence of VAP was

reported different, depending on the

definition, the type of hospital or ICU, the

population studied, and the type of rate

calculated and varies from 7% to 70% In a

large database, 1-day point prevalence study,

conducted in 1417 European ICUs, pneumoniaaccounted for 47% of nosocomial infections

12doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 13/94

Aero digestive ,upper airway + upper

digestive tract contribute pathogens

The primary route of 

VAP pathogenesis is a

combination of two

processes: bacterialcolonization of the aero

digestive (upper airway

+ upper digestive) tract

and the subsequentaspiration into the

lower airway.

13doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 14/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 15/94

Time frame of intubation and risk

Risk of pneumonia at

intubation days

 ± 3.3% per day at day 5

 ± 2.3% per day at day

10

 ± 1.3% per day at day

15

.

15doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 16/94

PAHOGENESIS ± The pathogenesis of 

ventilator-associated

pneumonia usually

requires that two

important processes

take place:

Bacterial colonization of 

the aero digestive tract

The aspiration of contaminated secretions

into the lower airway.

16doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 17/94

Mechanical device also

contributes the events

17doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 18/94

Etiology

Bacteria causemost cases of HAP,VAP, and HCAP

and manyinfections are polymicrobial;rates are especiallyhigh in patientswith ARDS

18doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 19/94

Causative Organisms

Early onset: ± Haemophilus influenza ± Streptococcus pneumoniae ± Staphylococcus aureus (methicillin sensitive) ± Escherichia coli ± Klebseilla

Late onset: ± Pseudomonas aeruginosa ± Acinetobacter ± Staphylococcus aureus (methicillin

resistant)

Most strains responsible for early onset VAP are antibiotic sensitive. Those responsible forlate onset VAP are usually multiple antibioticresistant

Am J Resp Crit Care (1995) 

19doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 20/94

Summary of pathogens responsible for VAP in a study of 420 patients.

Hunter J D Postgrad Med J 2006;82:172-178

©2006 by The Fellowship of Postgraduate Medicine20doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 21/94

Drug resistance a concern in Ventilator

Associated Pneumonias

A. baumanni was themost common emergingisolated pathogen manyof them were multidrug-

resistant (MDR) or pandrug-resistant (PDR). Theother common isolatedpathogens were K.

pneumoniae, P.aeruginosa andmethicillin-resistantS. aureus (MRSA).

21doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 22/94

Other Isolates in Ventilator associated

Pneumonias

 ± Pseudomonas aeruginosa. the most common MDR gram-negative bacterial pathogen

causing HAP/VAP, has intrinsic resistance to many

antimicrobial agents ± Klebsiella, Enterobacter, and Serratia species.

Klebsiella species ± intrinsically resistant to ampicillin and other aminopenicillins and

can acquire resistance to cephalosporins and aztreonam by the

production of extended-spectrum  ±lactamases (ESBLs)

 ± However ESBL-producing strains remain susceptible tocarbapenems ?

Ent erobact er species

C i t robact er and

Serrat ia species 22doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 23/94

 Acinetobacter species

 ± Acinetobacter species

More than 85% of isolates aresusceptible to

carbapenems, butresistance isincreasing , Mostrecent concern.

Stenotrophomonas

maltophilia, andBurkholderia cepacia:

 ± resistant tocarbapenems ?

23doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 24/94

N ewer Carbapenemases

As of June 2010, therewere three reportedcases of Enterobacteriaceae

isolates bearing thisnewly describedresistance mechanism inthe US, the CDC statedthat "All three U.S.isolates were frompatients who receivedrecent medical care inIndia."

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 25/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 26/94

Staphylococcus aureus and

Streptococcus pneumoniae

 ± Methicillin-resistant Staphylococcus aureus

vancomycin-intermediate S. aureus

 ± sensitive to linezolid

 ±linezolid resistance has emerged in S. aureus, but is currentlyrare ?

 ± Streptococcus pneumoniae and Haemophilus

influenzae.

sensitive to vancomycin or linezolid, and most remainsensitive to broadspectrum quinolones

26doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 27/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 28/94

Influenza too can cause VAP 

Nosocomial virus and fungal

infections are uncommon

causes of HAP and VAP in

immunocompetent patients.

Outbreaks of influenza haveoccurred sporadically and

risk of infection can be

substantially reduced with

widespread effective infection

control, vaccination, and use of anti influenza agents

28doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 29/94

F ungal pathogens can cause

VAP  ±F ungal 

 pathogens.

 Asper gillus

species

C and i d a

albicans

29doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 30/94

P athogenesis Entry of P athogens

Where do the bacteria come from?

 ± Tracheal colonization- via oropharyngeal

colonization or GI colonization

 ± Ventilator system

How do they get into the lung?

 ± Breakdown of normal host defenses

 ± Two main routes

Through the tube

Around the tube- microaspiration around ETT cuff 

30doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 31/94

Oropharyngeal colonization can be

source of VAP

Scannapieco et al showed a transition in thecolonization of dental plaques in patients inthe ICU

Control=25 subjects presenting to preventivedentistry clinic

Study group=34 noncardiac patientsadmitted to medical ICU at VA hospital(sampled within 12 hours of admission andevery third day)

31doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 32/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 33/94

Viral Pathogens

Outbreaks of HAP, VAP, andHCAP due to viruses, suchas influenza, parainfluenza,adenovirus, measles, andrespiratory Syncytial virushave been reported andare usually seasonal.

Influenza, pararinfluenza,adenovirus, andrespiratory Syncytial virus

account for 70% of thenosocomial viral cases of HAP,VAP, and HCAP

33doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 34/94

Bio films Many species, including

P seud omonas aerugi nosa

and St aphy lococcus

aureus, produce bio films,which surround the

organisms when attached

to endotracheal tubes,

and make them relatively

resistant to the actions of 

antibiotics and host

defences.

34doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 35/94

Bio films,

The surviving

organisms may

play a role inrelapses by

shedding infective

particles from theendotracheal tube

into the lower

respiratory trac35doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 36/94

Multidrug resistant organisms are

associated with

The prevalence of MDR  pathogens varies by patient population, hospital, andtype of ICU, which

underscores the need for local surveillance data

MDR pathogens are morecommonly isolated from

 patients with severe, chronic

underlying disease, thosewith risk factors for HCAP,and patients with late-onsetHAP or VAP

36doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 37/94

Diagnosis?

A pulmonogist with25+ yearsexperience guesses

he is only correct60% of the timewhen diagnosingpneumonia before

seeing the CXR. Ali tt le better than acoin-toss.

37doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 38/94

Diagnosis is imprecise and usually 

based on a Combination of 

 ±Clinical factors - fever or hypothermia;change in secretions; cough; apnea/bradycardia; tachypnea

 ±Microbiological fact ors - positivecultures of blood/sputum/tracheal

aspirate/pleural fluids

 ±CXR factors - new or changing infiltrates

38doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 39/94

Strategies in Diagnosis in VAP are

multifaceted Clinical

Strategy

Bacteriologic

Strategy

ComparingDiagnostic

Strategy39doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 40/94

Diagnostic practices

VAP

 ± Invasive versus non-invasive techniques

 ± BAL/PBB versus tracheal aspirate

 ± Quantitative versus non-quantitative methods

Infection definitions

 ± Clinician decision or standardised definitions

40doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 41/94

S pecimen collection for Optimal Results

Distal airway samples may be obtained by

using bronchoscopic or nonbronchoscopic

techniques. With nonbronchoscopic

techniques, a catheter is blindly advanced

through the endotracheal tube or

tracheostomy and wedged in the distal airway.

Various sampling methods include blindbronchial suction (BBS), blind BAL, and blind

PSB sampling.

41doctortvrao@gmail.com

t 2

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 42/94

Bacteriologic Strategy

Quantitative cultures can be performed onendotracheal aspirates or samples collected either 

 bronchoscopically or nonbronchoscopically,and each technique has itsown diagnostic thresholdand methodologiclimitations. The choice of method depends on localexpertise, experience,availability, and cost

42doctortvrao@gmail.com

tvrao 2

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 43/94

Slide 42

tvrao 2 doctortvrao, 7/18/2010

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 44/94

Nonquantitative or

semiquantitative airway sampling.

Gram staining and nonquantitative andsemiquantitative cultures of tracheal secretionshave the advantages of reproducibility and of 

requiring little technical expertise and nospecialized equipment or technique. However,these studies add little to the sensitivity andspecificity of the clinical diagnosis of VAP, as the

upper respiratory tract is rapidly, within hours of intubation, colonized by potential pulmonarypathogens, even when pneumonia is not present

43doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 45/94

Specimen collection

Tracheobronchial secretions were collected by

the pulmonologist , following specimen

collection guidelines, after tracheal instillation

of 5 ml saline. The specimens were sent to the

laboratory and cultivated within 1 hour of 

collection. A dilution of the tracheal aspirate

was prepared and inoculated with a calibratedloop on chocolate agar and MacConkey agar

44doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 46/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 47/94

Culture positivity true or false?

Qualitative cultures were considered positive

when the growth of any micro-organism

occurred and quantitative cultures were

considered positive when the growth of 105

colony-forming units (cfu)/ml or more was

observed. cultures from tracheal aspirates

were calculated according to standardformulae

46doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 48/94

Which is optimal sample ?

Despite numerous publications on the subject,

controversy still exists on the optimal method

of microbiological diagnosis of VAP,As the

trachea and tracheal tube rapidly become

colonised with bacteria in the critically ill

patient, cultures of sputum or tracheal

aspirates may simply yield colonising organism

47doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 49/94

Differentiates between pathogenic

from non pathogenic ?

Analysing samples using quantitative culture

techniques theoretically permits

differentiation between oropharyngeal

organisms present at low concentrations and

the higher concentrations of pathogenic

organisms.

48doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 50/94

WHY IS THERE NO GOLD STANDARD?

After more than 10 years of trying multiple

invasive and non-invasive diagnostic

techniques, the procedure which is specific,

sensitive, rapid and inexpensive is yet to be

developed. No studies have shown the

superiority of any specific diagnostic method

currently in use, thus, medical community still has no gold standard for the diagnosis of VAP 

49doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 51/94

Good Microbiology practices reduces

Antibiotic usage

Invasive tests such as bronchoscope BAL or

protected specimen brush (PSB) may avoid the

extended use of antibiotics for clinically

insignificant organisms, but no direct

consensus or evidence suggests that one test

is superior to the other; all have their

advantages and disadvantages.

doctortvrao@gmail.com 50

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 52/94

Precautions in collecting and

transporting

After proper hand washing and wearing sterile

gloves before suctioning, the endotracheal

secretions were collected by instilling 1-2 ml

of sterile normal saline into the endotracheal

tube and then collecting it back with the help

of sterile mucous trap. The specimen collected

was immediately transported to thelaboratory within one hour of collection.

doctortvrao@gmail.com 51

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 53/94

Gram stain is highly sensitive

Sputum or tracheal suction gram stain

NO ORGANISMS

in non-neutropenic pts.

NO HAP/VAP 94%

52doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 54/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 55/94

Bacterial culture of trachealsecretion

Qualitative culture- non specific

Semi-quantitative

culture- low specificity

Quantitativeculture : TS, BAL,

PSB- increase

specificity

54doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 56/94

Collection of bronchial Secretions

Distal airway samples may be obtained by

using bronchoscopic or nonbronchoscopic

techniques. With nonbronchoscopic

techniques, a catheter is blindly advancedthrough the endotracheal tube or

tracheostomy and wedged in the distal airway.

Various sampling methods include blindbronchial suction (BBS), blind BAL, and blind

PSB sampling.

55doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 57/94

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 58/94

Collection of bronchial Secretions

Distal airway samples may be obtained by

using bronchoscopic or nonbronchoscopic

techniques. With nonbronchoscopic

techniques, a catheter is blindly advancedthrough the endotracheal tube or

tracheostomy and wedged in the distal airway.

Various sampling methods include blindbronchial suction (BBS), blind BAL, and blind

PSB sampling.

57doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 59/94

The sensitivity of quantitative BAL is 42 to 93% with amean of 73%. Specificity is 45 to

100% with a mean of 82%. Specific affected area of thelung can be visualized and sampled

More accurate than sputum or tracheal aspirates

May enable physician to identify non-infectiouslesions

Detects intracellular organisms inB

AL

culturesquickly and specifically

with highly positive predictive value

doctortvrao@gmail.com 58

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 60/94

Bacterial culture of trachealsecretion

Qualitative culture

- non specific

Semi-quantitative culture

- low specificity

Quantitative culture : TS, BAL, PSB

- increase specificity

59doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 61/94

Protected Specimen Brush

ProBAL© PSB by Mill-Rose The protected specimen brush

technique for the diagnosis of pneumonia has been used for20 years. This bronchoscopictechnique use a sample

collection brush (protected bya sheath) inside the scopechannel until the suspectportion of the lower airwayhas been reached. The brush isthen extended into the desiredspecimen and withdrawn. Thistechnique was first describedin 1979 by Wimberly, et al.

doctortvrao@gmail.com 60

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 62/94

Semiquantitative

1+ : rare <10 colonies/plate

2+: few 10-102 colonies/plate3+: moderate >102-3 colonies/plate

4+: numerous >103-4 colonies/plate

5+: numerous >104 colonies/plate

61doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 63/94

Collection of bronchial Secretions

Distal airway samples may be obtained by

using bronchoscopic or nonbronchoscopic

techniques. With nonbronchoscopic

techniques, a catheter is blindly advancedthrough the endotracheal tube or

tracheostomy and wedged in the distal airway.

Various sampling methods include blindbronchial suction (BBS), blind BAL, and blind

PSB sampling.

62doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 64/94

Q ualitative and quantitative

Qualitative endotracheal aspirates are easy to

obtain but have a high false-positive rate in

ICU patients because of airway colonization.

When quantitative endotracheal-aspiratecultures are used, a cutoff value of 106 is the

most accurate, with a sensitivity of 38-82%

and a specificity of 72-85%

63doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 65/94

Differing opinions in specimen collection

Recent studies have consistently shown thatoutcome in VAP may not be influenced bywhether cultures are obtained by

bronchoscope or from tracheal aspiratescollected at the bedside. Furthermore, a costeffectiveness analysis strongly supported theemployment of tracheal aspirates in the

management of VAP. Ruiz M, Torres A, Ewig S, Marcos MA, Alcón A, Lledó R, Asejo MA,Maldonado M: Non-

invasive versus invasive microbial investigation in ventilator associated pneumonia:

evaluation of outcome. Am J Respir Crit Care Med 2000, 162:119-125.

doctortvrao@gmail.com 64

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 66/94

hi h h d f ll i i

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 67/94

Which methods of collection is

better

Two diagnostic strategies for ventilator-

associated pneumonia bronchoalveolar

lavage with quantitative culture of the

bronchoalveolar-lavage fluid and endotrachealaspiration with nonquantitative culture of the

aspirate are associated with similar clinical

outcomes and similar overall use of antibiotics A Randomized Trial of Diagnostic Techniques for Ventilator-Associated

Pneumonia N Engl J Med 2006; 355:2619-2630December 21, 2006

doctortvrao@gmail.com 66

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 68/94

False negative False Positive Results

Investigators reported

that the clinical diagnosis

of VAP is associated 30

35% false-negative and

2025% false-positive

results . And also, ICU

patients do not always

have systemic signs of 

infection due to theirunderlying disease

(chronic renal failure)

67doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 69/94

Other Supporting Bacterial Cultures

Bacteraemia and positive pleural effusioncultures are generally considered to be able toidentify the organisms causing the pneumonia,

if no other source of infection is found.Therefore, most experts recommend thatinvestigation of suspected VAP should includetaking two sets of blood samples for culture

and tapping pleural > 10 ml, even thoughspread to the blood or pleural space occursin < 10% of VAP

68doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 70/94

Multiresistant pathogens in Ventilator

associated pneumonias

The incidence of multiresistantpathogens is alsoclosely linked to localfactors and varieswidely from oneinstitution to another.Consequently, each ICU

must continuouslycollect meticulousepidemiologic data

69doctortvrao@gmail.com

b f

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 71/94

Uncommon microbes are often

missed

Legionella species , anaerobes

fungi viruses, and even

P neumocy st is cari nii should be

mentionedas potential causative

agents but are not considered to

be common in the context of pneumonia acquired during MV.

However, severalof these

causative agents may be more

common and potentially

underreportedbecause of difficulties involved with the

diagnostic

70doctortvrao@gmail.com

I l i l th d i

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 72/94

Immunological methods in

Diagnosis

A recently described immunological method

for the diagnosis of VAP holds great promise

for the future. The triggering receptor

expressed on myeloid cells (TREM-1) is a

member of the immunoglobulin super family,

and is involved in the acute inflammatory

response. Neutrophils express high levels of TREM-1 on exposure to infected tissues.

71doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 73/94

N ewer Methods in Diagnosis

Gibot and colleagues prospectively studied 148mechanically ventilated patients with suspectedVAP. A rapid immunoblot technique was used to

measure soluble triggering receptor expressedon myeloid cells TREM-1 in bronchoalveolarlavage fluid. They showed that the presence of soluble TREM-1 in the bronchoalveolar lavage(BAL) fluid was a highly accurate method for thediagnosis of fungal or bacterial pneumonia with asensitivity of 98% and a specificity of 90%.

72doctortvrao@gmail.com

H h li i i d f

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 74/94

H ow much a clinician needs from

Microbiology 

Culture results are currently used to guideadjustment or withdrawal of antibiotic therapyrather than to decide whether to treat or not.

The practice of changing therapy with cultureresults has resulted in reduced consumption of antibiotics.

Conversely, studies have shown that over-

treatment with antibiotics may select organismssuch as P seud omonas aerugi nosaand  

 Aci net obact er calcoacet icus

doctortvrao@gmail.com 73

E id b d l d

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 75/94

Mortality Mortality 

 Appropriate Appropriate Mortality Mortality 

InappropriateInappropriate Mortality Mortality 

Early Early  Mortality Mortality 

Evidence-based early andappropriate therapy in VAP

74doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 76/94

Benchmarking prescribing practice

Triggers to starting antibiotics

 ± Regular sampling versus clinician guided

 ± Timing in relation to investigation

Choice of antibiotic regimen ± Early empiric broad-spectrum cover versus narrow

spectrum with escalation

De-escalation practice

Duration of prescription

75doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 77/94

l f b l

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 78/94

Continuous Removal of Subglottic

Secretions

8VHDQ(7WXEH

ZLWKFRQWLQXRXVVXFWLRQWKURXJK

DGRUVDOOXPHQ

DERYHWKHFXII

WRSUHYHQW

GUDLQDJH

DFFXPXODWLRQ

8VHDQ(7WXEH

ZLWKFRQWLQXRXVVXFWLRQWKURXJK

DGRUVDOOXPHQ

DERYHWKHFXII

WRSUHYHQW

GUDLQDJH

DFFXPXODWLRQ77doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 79/94

No uniformity in treatment schedules

However, despite theseadvances, the majorityof issues related to themanagement of VAP

remain unresolved andare subject tocontroversy. This isparticularly true for the

diagnostic evaluation of the patient withsuspected VAP.

78doctortvrao@gmail.com

Clinical diagnosis of ventilator-associated 

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 80/94

g f

 pneumonia

What is not controversial? Clinical criteria for the diagnosis of VAP  

have a limited diagnostic accuracy .

This is true for single criteria such as infiltrates

in chest radiograph, fever or hypothermia,leukocytosis or leucopoenia, and increase inthe amount and/or purulence of tracheobronchial secretions, as well as fordiagnostic rules incorporating some of thesecriteria.

79doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 81/94

HandwashingHandwashing

What role does handwashing play innosocomial pneumonias?

The greatest role

80doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 82/94

VAP PreventionVAP Prevention

Wash hands before

and after 

suctioning,touching ventilator 

equipment, and/or 

coming into

contact with

respiratory

secretions.81doctortvrao@gmail.com

Epidemiological data differs from

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 83/94

Epidemiological data differs from

situations The incidence of 

multiresistantpathogens is alsoclosely linked to local

factors and varieswidely from oneinstitution to another.Consequently, each ICU

must continuouslycollect meticulousepidemiologic data

82doctortvrao@gmail.com

Can we deliver a successful

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 84/94

Can we deliver a successful

Treatment

Successful treatment of patients with VAP

remains a difficult and complex undertaking.

Despite broad clinical experience with this

disease, no consensus has been reachedconcerning issues as basic as the optimal

antimicrobial regimen or its duration. In fact,

to date, evaluation of various antimicrobialstrategies for the treatment of bacterial VAP

has been difficult for several reasons.

83doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 85/94

Supporting Evidences

Consequently, most

experts recommend that

two sets of blood cultures

and a thoracentesis for

nonloculated pleural

effusions of 10 mm in

diameter on a lateral

decubitus chest

radiograph should be partof the evaluation of 

suspected VAP

84doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 86/94

Handwashing

Hand washing is the single mostimportant (and easiest!!!) method forreducing the transmission of pathogens.

Use of waterless antisepticpreparations is also acceptable and mayincrease compliance.

85doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 87/94

Oral Care Dental plaque contains multiple pathogens

(may include s. aureus and p. aeruginosa) After 48 hours, normal oral flora of critically

ill pts changes to more virulent gram (-)organisms Aspiration of oral secretions around the cuff

and ETT occurs in all vented patients

VAP rates are reduced when oral caremeasures are included in a comprehensiveprevention program

86doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 88/94

P robiotics in VAP 

Probiotics prophylaxis of VAP using Lact obacillusr hamnosus GG appears safeand efficacious in a selectpopulation with a very high

risk of VAP, "Ultimately,probiotics may fulfil a role inantimicrobial stewardshipprograms given thereductions in antibioticconsumption.

American Jour nal of Respirat or y  and  C ri t ical C are Med ici ne.

doctortvrao@gmail.com 87

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 89/94

Interdisciplinary rivalry increases

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 90/94

Interdisciplinary rivalry increases

Mortality

VAP is an excellent

example of a problem

that can best be solved

by interdisciplinarycooperation rather than

interdisciplinary rivalry 

and devaluing the

contributions of selected members of 

the health care team.

89doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 91/94

Medical Profession is Changing from

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 92/94

Medical Profession is Changing from

Confidence to Confusion ? 

91doctortvrao@gmail.com

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 93/94

References American Thoracic Society. HAP in adults: diagnosis, assessment of severity, initial antimicrobial therapy

and preventive strategies. Am J Resp Crit Care 1995;153: 1711-1725.

Chastre J. et al. Ventilator Assosciated Pneumonia. Am J Respir Crit Care Med 2002; 10:364-368.

Cutler C> et al. Improving oral care in patients receiving mechanical ventilation. Am J Crit Care 2005; 14(5):389-394.

Grap M. et al. Preventing VAP: evidence-based care 2004; 16: 349-458.

Keenan S. et al. VAP: prevention, diagnosis, and therapy. Crit Care Clin 2002; 18(1): 107-125.

Kollef M. Prevention of hospital associated and ventilator associated pneumonia. Crit Care Med 2002; 32:

1396-1405. Marik, P. et al. One good turn deserves another. Crit Care Med 2002; 30(9): 2146-2148.

Anesthesiology: Pneumatikos, Ioannis A. M.D., Ph.D., F.C.C.P.; Dragoumanis, Christos K. M.D., Ph.D.;

Bouros, Demosthenes E. M.D., Ph.D., F.C.C.P. March 2009 - Volume 110 - Issue 3 - pp 673-680

Centers for Disease Control and Prevention, 2003. Rumbak, M. J. (2000). St rat egies for prevent ion and  

t reat ment . Journal of Respiratory Disease, 21 (5), p. 321;

Anesthesiology: Pneumatikos, Ioannis A. M.D., Ph.D., F.C.C.P.; Dragoumanis, Christos K. M.D., Ph.D.;

Bouros, Demosthenes E. M.D., Ph.D., F.C.C.P.vMarch 2009 - Volume 110 - Issue 3 - pp 673-680

Ventilator associated pneumoniaJ D Hunter Correspondence to: Dr J D Hunter Department of 

Anaesthetics and Intensive Care, Macclesfield District General Hospital, Victoria Road, Macclesfield SK10

3BL, UK; john.hunter@echeshire-tr.nwest.nhs.uk

doctortvrao@gmail.com 92

8/8/2019 138aVap Presentation Ramayya

http://slidepdf.com/reader/full/138avap-presentation-ramayya 94/94

P resented as Guest Lecture at Indian

 Association of Medical Microbiologists

(I  AMM)- KC held at M.S. Ramaiah Medical 

College, Bangalore India on 4th Sept 2010 

email

doctortvrao@gmail.com

top related